FDA Approves Landmark Drug for Lung Cancer Patients

Posted by Kassy Perry

Bonnie J. Addario Lung Cancer Foundation supports revolutionary immunotherapy drug

San Carlos, Calif. (March 4, 2015) Today, the Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the U.S. Food and Drug Administration’s approval of the Bristol-Meyers Squibb’s Opdivo immunotherapy drug for the treatment of lung cancer, the leading cause of cancer death in the U.S.

“It’s about time we revolutionize our approach to lung cancer treatment,” said Bonnie J. Addario, 10 year lung cancer survivor and founder of the ALCF. “Lung cancer has one of the highest mortality rates. There is significant need for treatment options that benefit patients and increase survival rates. This is a huge step in the right direction.”

Immunotherapy is a breakthrough treatment option that uses a patient’s immune system to help fight cancer, rather than using toxic chemotherapies. Opdivo is approved for patients diagnosed with squamous non-small cell lung cancer (NSCLC). NSCLC is one of the most common types of lung cancer and accounts for more than 85 percent of all diagnoses. Researcher’s understanding of the relationship between cancer and the immune systems has improved dramatically over the past decade. Through the development of a variety of immunotherapy treatments, along with strategies to combine them with existing treatments, researchers are working to address all cancers and extend the benefits of immunotherapy to a larger group of cancer patients.

“The FDA’s landmark approval will revolutionize our nation’s approach to cancer treatment,” said Addario. “We have worked with Bristol-Meyers for years and are proud to assist them in ushering in a new and hopeful era for lung cancer patients across the nation.”

For those interested in learning more about ALCF, visit and follow its activities on Twitter and Facebook.

About the Bonnie J. Addario Lung Cancer Foundation

The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest philanthropies (patient-founded, patient-focused, and patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation’s goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. The ALCF was established on March 1, 2006 as a 501c(3) non-profit organization and has raised more than $20 million for lung cancer research and related programs.